glp-1 obesity drug news today oct 23 2025 CVS deal puts Lilly on equal footing with Novo Obesity GLP-1 Market
Description
This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
In summary, GLP-1 drugs offer significant advantages for individuals with type 2 diabetes or weight management concerns
Medicare has never paid for weight-loss drugs at scale
Conclusion GLP-1 RAs may significantly lower the combined risk of mortality and hospitalization in patients with HFpEF
